Cantor Fitzgerald Brokers Reduce Earnings Estimates for ACAD

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Cantor Fitzgerald lowered their FY2025 EPS estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Thursday, February 27th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will post earnings of $0.15 per share for the year, down from their prior forecast of $0.24. Cantor Fitzgerald has a “Overweight” rating and a $28.00 price target on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share.

A number of other equities analysts have also recently issued reports on ACAD. StockNews.com cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday. Guggenheim cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They set a “hold” rating and a $22.00 target price on the stock. Nine analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

ACADIA Pharmaceuticals Price Performance

Shares of ACADIA Pharmaceuticals stock opened at $19.60 on Friday. The stock has a market cap of $3.26 billion, a price-to-earnings ratio of 25.13 and a beta of 0.37. The firm’s 50-day moving average is $18.42 and its 200 day moving average is $16.85. ACADIA Pharmaceuticals has a 1 year low of $14.15 and a 1 year high of $24.53.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Virtus Fund Advisers LLC bought a new position in shares of ACADIA Pharmaceuticals in the 4th quarter worth approximately $39,000. R Squared Ltd purchased a new stake in ACADIA Pharmaceuticals in the 4th quarter worth approximately $47,000. Quest Partners LLC increased its holdings in ACADIA Pharmaceuticals by 42.3% in the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 1,047 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in ACADIA Pharmaceuticals in the 4th quarter worth approximately $64,000. Finally, KBC Group NV increased its holdings in ACADIA Pharmaceuticals by 67.0% in the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 2,044 shares in the last quarter. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.